- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
FDA Approves Medinol’s Drug-Eluting Coronary Stent System
The EluNIR-PERL drug-eluting stent is used for the treatment of coronary artery disease.
Medinol announced that its EluNIR-PERL drug-eluting stent (DES) received approval from FDA. The device is used in the treatment of coronary heart disease.
The design of the stent allows for more precise navigation and placement in complex anatomies.
In a press release, Medinol CEO Yoram Richter said, “We are pleased to bring technologies to the U.S. that focus both on benefit to patients as well as unique and meaningful advantages to surgeons, allowing for precise stent placement, shorter procedure times and reduced radiation exposure.”
In the same press release, CoSo Health CEO Jae Lee stated that CoSo would distribute the device.
"We are proud to distribute one of the world's best drug-eluting stents via our intuitive and easy-to-use SaaS+ platform, which reduces layers in the supply chain," Lee said.
SOURCE
(Oct 24 2023); CoSo Health; Medinol Receives FDA Approval for Next Generation EluNIR-PERL Drug-Eluting Coronary Stent System; https://www.prnewswire.com/news-releases/medinol-receives-fda-approval-for-next-generation-elunir-perl-drug-eluting-coronary-stent-system-301965041.html
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
The State of Mining Data Insights in the Life Sciences Industry – 2024
April 30th 2024A Frost & Sullivan industry-wide survey reveals which insights most pharmaceutical companies have mastered and which are still painful or impossible to extract and details the complexity of the process, the confidence companies have in their findings, and more. Hear Web Sun, President and Co-founder of Komodo Health, share what's driving these challenges and how you can overcome them.
